Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. (NASDAQ: GALT) generates frequent news as a clinical-stage biopharmaceutical company developing galectin-targeted therapies for chronic liver disease and cancer. Most company updates focus on belapectin, its carbohydrate-based galectin-3 inhibitor, and the lead program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension.
On this page, readers can follow news about clinical data from the NAVIGATE trial and related analyses, including outcomes on liver stiffness by FibroScan, Enhanced Liver Fibrosis (ELF) scores, and serum biomarkers such as PRO-C3, YKL-40, and PRO-C4. Galectin Therapeutics often reports how these measures relate to the incidence of new esophageal varices and portal hypertension risk categories in patients with compensated MASH cirrhosis.
News items also cover regulatory interactions with the U.S. Food and Drug Administration, such as Type C meeting requests, written feedback on trial design, and plans for potential pivotal Phase 3 development of belapectin. Investors can find announcements about Fast Track designation, presentation of NAVIGATE data at major liver disease meetings like AASLD and EASL, and participation in investor conferences and virtual key opinion leader events.
In addition, Galectin Therapeutics issues press releases on quarterly financial results, new or extended lines of credit and convertible notes, and corporate governance matters. These updates provide context on the company’s capital resources, development priorities, and timing of planned activities. For anyone tracking GALT, this news feed offers a centralized view of clinical milestones, regulatory developments, financing arrangements, and strategic communications related to belapectin and the company’s broader galectin-targeted pipeline.
Galectin Therapeutics (NASDAQ: GALT) reported 2025 results and a business update highlighting progress on belapectin for MASH cirrhosis and portal hypertension.
Key facts: R&D expenses fell to $14.3M, net loss improved to $31.0M, cash of $17.7M plus a $10M credit line extends runway to April 2027. NAVIGATE showed per-protocol varices reductions and multiple supportive biomarker signals; an FDA meeting is planned Q2 2026.
Galectin Therapeutics (NASDAQ:GALT) appointed Henry Brem, M.D., as an independent director on March 17, 2026. Dr. Brem is a neurosurgeon-scientist from Johns Hopkins with extensive translational-medicine experience, NIH funding over four decades, 416+ peer-reviewed papers, patents, and membership in the National Academy of Medicine.
This addition aims to strengthen clinical and regulatory expertise as Galectin advances belapectin for patients with MASH cirrhosis and portal hypertension.
Galectin Therapeutics (NASDAQ:GALT) will host a virtual key opinion leader event on March 10, 2026 at 12:00 PM ET to discuss belapectin development for MASH cirrhosis and portal hypertension.
The event features KOLs Naga P. Chalasani, MD and Naim Alkhouri, MD, and will highlight updated NAVIGATE Phase 3 results and include a live Q&A.
Galectin Therapeutics (NASDAQ:GALT) reported an FDA written response to its Type C meeting request on belapectin, noting alignment on the proposed registration-trial patient population and prior agreement to use a centralized, blinded endoscopy review for variceal assessment.
The company will request a follow-up Type C meeting to finalize unresolved trial-design components and present recently generated biomarker data from the AASLD meeting. Separately, chairman Richard E. Uihlein provided a new $10 million unsecured, convertible line of credit and extended existing convertible facilities to June 30, 2027, supporting cash sufficiency through at least March 2027.
Galectin Therapeutics (NASDAQ: GALT) reported Q3 2025 results and a clinical update on belapectin from the NAVIGATE trial presented at AASLD. The company submitted the NAVIGATE data package to the FDA and expects feedback by year-end. Key 18-month biomarker findings showed reductions in liver stiffness (FibroScan), ELF, PRO-C3, YKL-40, and improvements in Baveno VII portal hypertension categories, with the 2 mg/kg dose showing a shift to no/low-risk CSPH (42.0% to 56.8%).
Q3 cash was $11.5M, a $10M chairman line of credit was added July 8, 2025, R&D was $2.6M, G&A $1.6M, and net loss was $8.2M (−$0.13/share).
Galectin Therapeutics (NASDAQ:GALT) presented NAVIGATE Phase 2b results for belapectin in 355 patients with compensated MASH cirrhosis and portal hypertension at AASLD 2025.
Key findings: randomization 1:1:1 to IV belapectin 2 mg/kg, 4 mg/kg or placebo every other week for 78 weeks; ELF >11.3 new varices 22.7% (2 mg/kg) vs 42.9% (placebo); Pro-C3 mean change at 78 weeks: –6.4 ng/mL (2 mg/kg) vs –4.5 ng/mL (placebo); sustained reduction in new varices persisted through 36 months (cumulative incidence 12.4% for 2 mg/kg vs 23.4% placebo). Safety profile comparable to placebo.
Galectin Therapeutics (NASDAQ: GALT) will present at the H.C. Wainwright 9th Annual MASH Virtual Investor Conference on October 21, 2025.
Company presentation is scheduled for October 21, 2025 at 7:00 AM ET, with a live webcast and archived replay available on the company’s Events & Presentations page in Investors. Management attending includes Joel Lewis, CEO, and Khurram Jamil, M.D., CMO, who will be available for one-on-one meetings during the conference; interested investors should contact their H.C. Wainwright representative to arrange meetings.
Galectin Therapeutics (NASDAQ: GALT) will present new clinical data from the NAVIGATE trial at the AASLD Liver Meeting 2025 in Washington, DC, November 7-11, 2025. The company will deliver one oral presentation and one poster highlighting belapectin results in MASH cirrhosis and portal hypertension.
Oral: "Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months" on Nov 10, 2025, 2:00–3:30 PM ET (Abstract 0145). Poster: "Belapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months" on Nov 8, 2025, 8:00 AM–5:00 PM ET (Abstract 2375). Presentations will be viewable by AASLD attendees and posted on the company's Events & Presentations page after the congress.
Galectin Therapeutics (NASDAQ:GALT), a leader in galectin protein-targeted therapeutics, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company's presentation is scheduled for September 8, 2025, at 1:00 PM ET.
CEO Joel Lewis and CMO Dr. Khurram Jamil will be available for one-on-one meetings during the conference. Investors can access the presentation through a live webcast, which will also be archived on the company's investor relations website.
Galectin Therapeutics (NASDAQ:GALT) reported Q2 2025 financial results and provided updates on their NAVIGATE trial for belapectin in MASH cirrhosis patients. The company ended Q2 with $13.8 million in cash and secured an additional $10 million credit line from its chairman in July 2025.
Key financial metrics include a reduced net loss of $7.6 million ($0.12 per share) compared to $12.4 million in Q2 2024, and significantly lower R&D expenses of $3.3 million vs $9.8 million year-over-year. The company presented promising NAVIGATE trial results at EASL 2025, showing sustained efficacy in reducing liver stiffness and fewer patients experiencing clinically meaningful worsening in the belapectin arm.